臨床眼科78巻13号

2024年12月発行

今月の話題

アトピー性皮膚炎患者におけるデュピルマブ関連結膜炎

著者： 庄司純¹ 安達瑠美¹

所属機関： ¹日本大学医学部視覚科学系眼科学分野

ページ範囲：P.1457 - P.1464

文献概要

　デュピルマブ関連結膜炎は，アトピー性皮膚炎に対するデュピルマブ抗体療法中に発症する高度の球結膜充血を特徴とする結膜炎である。眼科医は，皮膚科との診療連携と治療介入により適切に結膜炎をコントロールすることが求められる。

参考文献

1）佐伯秀久，大矢幸弘，吉田淳一，他：アトピー性皮膚炎診療ガイドライン2021．日皮会誌131：2691-2777，2021

2）Harb H, Chatila TA：Mechanisms of dupilumab. Clin Exp Allergy 50：5-14, 2020

3）Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al：Conjunctivitis in dupilumab clinical trials. Br J Dermatol 181：459-473, 2019

4）Wu KK, Borba AJ, Deng PH, et al：Association between atopic dermatitis and conjunctivitis in adults：a population-based study in the United States. J Dermatolog Treat 32：455-459, 2021

5）Nahum Y, Mimouni M, Livny E, et al：Dupilumab-induced ocular surface disease（DIOSD）in patients with atopic dermatitis：clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Br J Ophthalmol 104：776-779, 2020

6）Bakker DS, Ariens LFM, van Luijk C, et al：Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol 180：1248-1249, 2019

7）Dogru M, Asano-Kato N, Tanaka M, et al：Ocular surface and MUC5AC alterations in atopic patients with corneal shield ulcers. Curr Eye Res 30：897-908, 2005

8）Horinaka M, Shoji J, Tomioka A, et al：Alterations in mucin-associated gene expression on the ocular surface in active and stable stages of atopic and vernal keratoconjunctivitis. J Ophthalmol 2021：9914786, 2021

9）Bakker DS, Ter Linde JJM, Amini MM, et al：Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines：a case series study. Allergy 76：3814-3817, 2021

10）Thormann K, Lüthi AS, Deniau F, et al：Dupilumab-associated ocular surface disease is chalacterized by a shift from Th2/Th17 toward Th1/Th17 inflammation. Allergy 79：937-948, 2024

11）Heibel HD, Hendricks AJ, Foshee JP, et al：Rosacea associated with dupilumab therapy. J Dermatolog Treat 32：114-116, 2021

12）Ricardo-Gonzalez RR, Kotas ME, O'Leary CE, et al：Innate type 2 immunity controls hair follicle commensalism by Demodex mites. Immunity 55：1891-1908.e12, 2022

13）Thyssen JP：Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels? Br J Dermatology 178：1220, 2018

14）Achten R, Thijs J, van der Wal M, et al：Dupilumab-associated ocular surface disease in atopic dermatitis patients：clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis. Allergy 78：2266-2276, 2023

15）Fukuda K, Ishida W, Kishimoto T, et al：Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis. Allergol Int 68：383-384, 2019

16）Tauqeer Z, Jinno SE, Chung CW, et al：Clinical characteristics and treatment for dupilumab-related ocular complications in atopic dermatitis patients. Clin Ophthalmol 16：947-958, 2022

17）Hébert M, Qi SR, You E, et al：Characterising the chronicity of dupilumab-associated ocular surface disease：an analysis of a retrospective case series. BMJ Open Ophthalmol 7：e000947, 2022

18）Thyssen JP, de Bruin-Weller MS, Paller AS, et al：Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy—international eczema council survey and opinion. J Eur Acad Dermatol Venereol 33：1224-1231, 2019

19）Popiela MZ, Barbara R, Turnbull AMJ, et al：Dupilumab-associated ocular surface disease：presentation, management and long-term sequelae. Eye（Lond） 35：3277-3284, 2021

20）Adachi R, Shoji J, Hirota A, et al：Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on ocular surface：a case report. Allergy Asthma Clin Immunol 18：89, 2022

21）Wollenberg A, Ariens L, Thurau S, et al：Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract 6：1778-1780.e1, 2018

22）Foley P, Kerdraon YA, Hogden JP, et al：Dupilumab-associated ocular surface disease：An interdisciplinary decision framework for prescribers in the Australian setting. Australias J Dermatol 63：421-436, 2022